Behavioural, Virological And Immunological Factors Influencing Hepatitis C Virus Infection In Injecting Drug Users
Funder
National Health and Medical Research Council
Funding Amount
$963,437.00
Summary
The hepatitis C virus (HCV) is a major public health problem affecting over 170 million people worldwide. In Australia an estimated 157,000 people have HCV and are at risk of serious disease, and 16,000 new infections occur each year. Treating HCV-related disease is expensive, and this healthcare burden is projected to grow significantly in coming years. Almost all new HCV infections in Australia occur among injecting drug users (IDUs), and despite our world-leading prevention programs, the viru ....The hepatitis C virus (HCV) is a major public health problem affecting over 170 million people worldwide. In Australia an estimated 157,000 people have HCV and are at risk of serious disease, and 16,000 new infections occur each year. Treating HCV-related disease is expensive, and this healthcare burden is projected to grow significantly in coming years. Almost all new HCV infections in Australia occur among injecting drug users (IDUs), and despite our world-leading prevention programs, the virus is spreading. Consensus is emerging that the best hope for control of HCV and related disease lies in a vaccine; our research will lay much of the groundwork for its development. The applicants' research to date shows that IDUs are being infected with HCV more frequently than previously assumed, that many carry multiple strains, and that dominant strains vary rapidly in individuals over time. These results reinforce the view that our prevention methods will not reduce infection rates and that current anti-viral treatments are not the solution. Nevertheless, we also found that some IDUs remain free of HCV infection despite risky behaviour with infected associates; intensive study of the immune functioning of these persistently non-infected individuals holds promise for vaccine development. In our proposed research, a collaboration of leading Australian epidemiologists, virologists and immunologists, we will recruit 210 young IDUs and follow them regularly for two years. Recruits will describe their social networks and nominate IDUs with whom they inject, provide blood samples and be interviewed about their behaviour at 3-month intervals. Individuals with recent and resolved HCV infection, change of dominant strain and lack of infection despite risky behaviour will be identified and their blood analysed for genetic factors that may be linked to immune protection. The outcomes will be crucial to the development and trialling of a vaccine against HCV.Read moreRead less
Risk Of Hepatitis C Reinfection Among People With Current Injecting Drug Use Following Successful HCV Treatment
Funder
National Health and Medical Research Council
Funding Amount
$2,245,228.00
Summary
In Australia, hepatitis C (HCV)-related morbidity and mortality are rising. One of the most important recent breakthroughs in clinical medicine is the approval of safe, simple, interferon-free HCV therapies with cure rates >95%. Although people who inject drugs account for the majority of new and existing cases of HCV, reinfection following treatment can occur. The goal of this Project Grant is to examine HCV treatment and reinfection following successful therapy among people who inject drugs ....In Australia, hepatitis C (HCV)-related morbidity and mortality are rising. One of the most important recent breakthroughs in clinical medicine is the approval of safe, simple, interferon-free HCV therapies with cure rates >95%. Although people who inject drugs account for the majority of new and existing cases of HCV, reinfection following treatment can occur. The goal of this Project Grant is to examine HCV treatment and reinfection following successful therapy among people who inject drugs.Read moreRead less
Hepatitis C Treatment-as-prevention In The Prison Setting
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
The burden of hepatitis C virus (HCV) infection in Australia is rising with prison settings being a major reservoir of HCV infection. This study evaluates the feasibility of a rapid scale-up of a new highly effective, short and tolerable HCV therapy and its impact on HCV transmission in the prison setting. This is the first HCV treatment-as-prevention study in prisons having strong potentials to inform public health policy nationally and internationally.
Prevention Of Sexually Transmitted Infections (STIs) And Blood Borne Viruses (BBVs) In Victoria's Vulnerable Populations: The Impact Of Early And Regular Testing.
Funder
National Health and Medical Research Council
Funding Amount
$96,183.00
Summary
The primary aim of this research is to investigate the relationship between early and regular testing of STIs and BBVs and transmission outcomes to inform effective strategies to prevent ongoing transmission of STIs and BBVs in at-risk populations. Specifically it will examine HIV, chlamydia, syphilis and gonorrhoea in men who have sex with men (MSM) in Victoria. This project will aim to identify prevention and health promotion strategies and methods of implementation to reduce the individual an ....The primary aim of this research is to investigate the relationship between early and regular testing of STIs and BBVs and transmission outcomes to inform effective strategies to prevent ongoing transmission of STIs and BBVs in at-risk populations. Specifically it will examine HIV, chlamydia, syphilis and gonorrhoea in men who have sex with men (MSM) in Victoria. This project will aim to identify prevention and health promotion strategies and methods of implementation to reduce the individual and community cost associated with STIs and BBVs.Read moreRead less
Towards HIV And Hepatitis C Elimination: Real-world Trials And Innovations In Disease Surveillance
Funder
National Health and Medical Research Council
Funding Amount
$640,210.00
Summary
Over the next five years I will undertake a program of research centred on developing and implementing strategies to help eliminate hepatitis C and HIV as major public health problems. In particular, I will use innovative monitoring systems and field trials to explore ways to diagnose and treat HIV and hepatitis C in vulnerable populations in a more timely way and study the influence this has on reducing the onward transmission of these infections to others.